|Free Dividend Report|
|Stock Splits Calendar|
|KBIO Stock Split History|
|Preferred Stock Newsletter|
|Top Option Ideas|
|Stock Message Boards|
KBIO (KBIO) has 1 split in our KBIO split history database. The split for KBIO took place on July 14, 2015. This was a 1 for 8 reverse split, meaning for each 8 shares of KBIO owned pre-split, the shareholder now owned 1 share. For example, a 1000 share position pre-split, became a 125 share position following the split.
When a company such as KBIO conducts a reverse share split, it is usually because shares have fallen to a lower per-share pricepoint than the company would like. This can be important because, for example, certain types of mutual funds might have a limit governing which stocks they may buy, based upon per-share price. The $5 and $10 pricepoints tend to be important in this regard. Stock exchanges also tend to look at per-share price, setting a lower limit for listing eligibility. So when a company does a reverse split, it is looking mathematically at the market capitalization before and after the reverse split takes place, and concluding that if the market capitilization remains stable, the reduced share count should result in a higher price per share.
Looking at the KBIO split history from start to finish, an original position size of 1000 shares would have turned into 125 today. Below, we examine the compound annual growth rate — CAGR for short — of an investment into KBIO shares, starting with a $10,000 purchase of KBIO, presented on a split-history-adjusted basis factoring in the complete KBIO split history.
Growth of $10,000.00
Without Dividends Reinvested
|Average Annual Total Return:||-52.71%|
|Kalobios Pharmaceuticals is a biopharmaceutical company focused on the development of monoclonal antibody therapeutics. Using Co.'s Humaneered® antibody technology, Co. has produced a portfolio of antibodies to treat medical conditions with a primary clinical focus on respiratory diseases and cancer. Co. has developed three monoclonal antibodies to the clinical development stage: KB004, which is a Humaneered® anti-EphA3 monoclonal antibody; KB003, which is a Humaneered® anti-granulocyte macrophage colony-stimulating factor monoclonal antibody; and KB001-A, which is a Humaneered® developed for the prevention and treatment of Pseudomonas aeruginosa infections. According to our KBIO split history records, KBIO has had 1 split.|
|KBIO Split History Table|
|07/14/2015||1 for 8|
|Healthcare Stock Splits|
|KBIO is categorized under the Healthcare sector; below are some other companies in the same sector that also have a history of stock splits:|